CRISPR Therapeutics stock drops 9% after CEO sale filing — what CRSP investors watch next week

CRISPR Therapeutics AG shares dropped 8.7% on Friday, ending the day at $55.52. The stock moved sharply between $61.01 and $55.07 during a choppy session that saw roughly 2.4 million shares change hands.

24 January 2026

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares climbed $4.59, or 3.5%, to $135.73 in Friday afternoon trading, building on a strong two-day surge and hitting new highs. The stock started the day at $131.26 and fluctuated between $130.65 and $136.26, with roughly 8.8 million shares traded.

23 January 2026

Biotechnology·NYSE:GILD·NYSE:JNJ·NYSE:MRK·Pharmaceutical News·Stock Market

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences shares climbed roughly 2% in premarket Friday, adding to a rollercoaster week for the lightly traded biotech. Investors were reacting to the company’s newest regulatory update. The stock last changed hands near $0.85.

23 January 2026

Biotechnology·NASDAQ:REVB·Stock Market

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics AG shares slipped about 0.5% to $60.51 in premarket trading on Friday, following a sharp 11.1% gain the previous day. The stock closed at $60.81 on Thursday after hitting an intraday high of $60.86 and seeing over 3.4 million shares change hands. Investors were reacting to an insider-sale filing.

23 January 2026

Biotechnology·NASDAQ:CRSP·Stock Market

Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

Regencell Bioscience Holdings Ltd shares climbed 16.3% to $35.77 in premarket trading Friday, building on a steep rise from the day before.

23 January 2026

Biotechnology·NASDAQ:RGC·Stock Market

CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL Ltd shares closed Friday 0.7% higher at A$179.62, building on Thursday’s 1.3% rise. The stock fluctuated between A$179.33 and A$180.80 during the session, with roughly 1.01 million shares traded.

23 January 2026

ASX News·ASX:CSL·Biotechnology·Stock Market

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna shares surged 4.2% to $51.87 in after-hours trading Thursday, following an earlier jump of about 11% to $55.17 on heavy volume—more than 34 million shares changed hands. CEO Stephane Bancel told Bloomberg TV the company won’t invest in new late-stage vaccine trials, pointing to growing resistance from U.S. officials. He cautioned that the U.S. market is becoming less dependable. “You cannot make a return on investment if you don’t have access to the U.S. market,” Bancel said.

23 January 2026

Biotechnology·NASDAQ:MRNA·Stock Market

GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus

Shares of GRAIL surged 13.2% to $114.41 Thursday afternoon, topping out at an intraday high of $118.50 earlier in the session.

22 January 2026

Biotechnology·NASDAQ:GRAL.O

Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

Thermo Fisher Scientific Inc shares rose $2.03, or 0.3%, to $638.33 on Thursday afternoon, after briefly climbing as high as $643.66 earlier in the session.

22 January 2026

Biotechnology·NYSE:TMO·Stock Market

Regencell Bioscience (RGC) stock price jumps 37% again as the latest swing hits Nasdaq screens

Shares of Regencell Bioscience Holdings Limited jumped roughly 37% to $29.98 in afternoon trading Thursday, rebounding sharply from earlier dips. The stock swung between $20.91 and $30.78, with around 1 million shares changing hands by 1:19 p.m. EST.

22 January 2026

Biotechnology·Nasdaq·NASDAQ:RGC·Stock Market

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares climbed 7.7% to $53.65 Thursday morning, extending gains fueled by fresh long-term data on its experimental personalized cancer vaccine, created in partnership with Merck.

22 January 2026

Biotechnology·NASDAQ:MRNA·NYSE:MRK

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex Pharmaceuticals shares jumped 4.31%, closing Wednesday at $461.14 and marking their third straight session of gains. Trading volume climbed past the stock’s 50-day average. VRTX outperformed peers like AbbVie, Krystal Biotech, and Arcturus Therapeutics, while the S&P 500 and Dow each gained over 1%.

22 January 2026

Biotechnology·Earnings Reports·NASDAQ:VRTX·Stock Market

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares were flat at $49.81 in premarket trading on Thursday, after the stock jumped 15.8% in the previous session.

22 January 2026

Biotechnology·NASDAQ:MRNA·NYSE:MRK

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

ImmunityBio shares dropped roughly 2% to $6.35 in Wednesday afternoon trading, as investors pared back after the biotech’s recent regulatory update. The stock swung between $5.74 and $6.64, with around 67 million shares changing hands.

21 January 2026

Biotechnology·NASDAQ:IBRX·Stock Market

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Shares of Corvus Pharmaceuticals, Inc. dropped nearly 8%, slipping to $19.68 in premarket trading Wednesday. The decline follows the company's announcement of an underwritten public offering worth $150 million in common stock and pre-funded warrants. These warrants let investors lock in shares now by paying most of the price upfront, with the option to buy later. Jefferies and Goldman Sachs are heading the deal, which also includes a 30-day over-allotment option allowing underwriters to purchase an extra $22.5 million in shares.

21 January 2026

Biotechnology·NASDAQ:CRVS·Pharmaceuticals·Stock Market

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck & Co shares held steady on Tuesday following news that the company's personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda. By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating between $107.06 and $109.11.

20 January 2026

Biotechnology·NASDAQ:MRNA·NYSE:MRK·Pharmaceuticals·Stock Market

Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

Qiagen’s shares in the U.S. surged 15.9% to $55.13 on Tuesday after reports surfaced that the molecular diagnostics firm is exploring strategic options, including a potential sale, amid renewed takeover interest. The term often signals major moves like a sale; Qiagen has yet to comment.

20 January 2026

Biotechnology·NYSE:QGEN·Stock Market

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

ImmunityBio shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA.

20 January 2026

Biotechnology·NASDAQ:IBRX.O·Stock Market

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio shares jumped on Friday and look set to remain in the spotlight when U.S. markets open again. The company revealed a steep rise in preliminary sales for its bladder cancer immunotherapy ANKTIVA, alongside a quicker-than-anticipated pace in trial enrollments.

17 January 2026

Biotechnology·Healthcare News·NASDAQ:IBO·Stock Market

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

Thermo Fisher Scientific shares dipped 0.9% to close at $618.72 on Friday, then stayed close to that price in after-hours trading. During the day, the stock fluctuated between $618.20 and $629.50. Trading volume hit roughly 2.9 million shares, matching its typical daily activity.

17 January 2026

Biotechnology·Earnings Reports·NYSE:TMO·Stock Market

Previous 1 … 7 8 9 10 11 … 22 Next

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus

Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

Regencell Bioscience (RGC) stock price jumps 37% again as the latest swing hits Nasdaq screens

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

TechStock² Updates

Gold Remains Over $4,600 as Treasury Buybacks Spark Dollar-Debasement Trade

Take-Two Shares Slip 2.1% With Netflix Preview of GTA VI Marking Final Launch Phase

U.S. 10-Year Treasury yield climbs to 4.67% ahead of Warsh’s Jackson Hole address

Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]

Microsoft launches $899 Xbox Series X25 in bid to gauge pricing power as console revenue drops 29%

US Stock Market Today Updates

Asia Stock Market Today Updates

UK Stock Market Today Updates

Australia Stock Market Today Updates

Top Stock Picks

NVIDIA

Meta Platforms

Alphabet

Amazon

Microsoft

Investment Disclaimer